icerwatch: analysis & COMMENTARY

The Last Word: ICER’s review of Anti-B-Cell Maturation Antigen CAR T-Cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myelomas

ICERWatch Analysis

In another final report, ICER uses its assumption-driven simulation models to conclude that two new treatments are not worth the cost.  

The last word: icer’s review of Benlysta and lupkunis for lupus nephritis 

ICERWatch Analysis

ICER’s flawed methodologies and impossible measurements continue unabated in its final report on treatments for lupus nephritis. 

damaged goods: imaginary icer value assessments and the department of veterans affairs (VA)

ICERWatch Analysis

The QALY is a mathematically impossible construct.  So what are the benefits — if any — of the collaboration between ICER and the Department of Veterans Affairs? 

the truth is out there: icer’s commitment to imaginary approximate information

ICERWatch Analysis

For ICER, evidence to support formulary decisions is created through imaginary simulation modeling, not through the standards of normal science.  This is not a sound basis for formulary decisions.

 

understanding measurement: why icer is wrong

ICERWatch Analysis

 ICER uses a reference case cost-per-QALY value assessment framework to evaluate treatment therapies.  There are a number of reasons this methodology is flawed and should not be used.  But the most fundamental issue is ICER does not seem to understand the limitations of measurement.

Abandoning icer lifetime QALYs

ICERWatch Analysis

The lieftime QALY should be abandoned.  And ICER’s reliance on the lifetime QALY makes ICER an unnecessary distraction.